Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Editas Medicine to Participate in Upcoming Investor Conferences
09:00am, Wednesday, 28'th Aug 2024
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcom
Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down
10:35am, Thursday, 08'th Aug 2024
Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates
09:05am, Wednesday, 07'th Aug 2024
Editas Medicine (EDIT) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.56 per share a year ago.
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
07:00am, Wednesday, 07'th Aug 2024
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financ
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
07:00am, Wednesday, 31'st Jul 2024
CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wed
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
11:30am, Wednesday, 17'th Jul 2024
Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology. Examples include CRISPR and other gene-editing technologies.
3 Profitable CRISPR Stocks Earning Analysts' Praise
07:59am, Tuesday, 09'th Jul 2024
CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organism
The 3 Best Gene Editing Stocks to Buy in July 2024
09:00am, Monday, 08'th Jul 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier gene
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
09:33pm, Wednesday, 26'th Jun 2024
Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
08:00am, Tuesday, 25'th Jun 2024
Gene-editing stocks has been gaining substantial attention, as the industry holds the potential to revolutionize medicine. From curing genetic disorders to enhancing agricultural productivity, the app
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
09:15am, Monday, 17'th Jun 2024
Editas (EDIT) reports positive new safety and efficacy data from the RUBY and EdiTHAL studies evaluating its investigational gene therapy, reni-cel, for SCD and TDT, respectively.
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion
Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)
08:25pm, Wednesday, 15'th May 2024
Editas Medicine, Inc. (NASDAQ:EDIT ) RBC Capital Markets Global Healthcare Conference Call May 15, 2024 2:05 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Conference Call Partic
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and
